Safety and efficacy of FTY720 in adult patients who receive a kidney transplant.

Trial Profile

Safety and efficacy of FTY720 in adult patients who receive a kidney transplant.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 14 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Nov 2011 Planned end date (Mar 2006) added as reported by ClinicalTrials.gov.
    • 29 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top